Novartis to take U.S. drug patent case to Supreme Court

Yichang Hec Changjiang Pharmaceutical Co

21/09/2022 06:17

ZURICH, Sept 21 (Reuters) - Novartis AG  NOVN.S  plans to
ask the U.S. Supreme court to uphold the validity of a patent it
holds on the dosing regimen for multiple sclerosis drug Gilenya
after suffering a setback in a federal appeals court ruling, the
Swiss drugmaker said on Wednesday.
    The ruling meant HEC Pharma and other drugmakers would 
potentially be able to launch a generic version of 0.5mg Gilenya
imminently, pending any other judicial actions, it said.
    "Should generics launch in the US, we expect FY 2022 sales
to be negatively impacted by USD 0.3bn. With regard to 2022 Full
Year Guidance for Group sales and core operating income growth,
we continue to expect both in the mid-single digit range, in
constant currencies," it added.
    

 (Reporting by Michael Shields
Editing by Paul Carrel)
 ((Michael.Shields@thomsonreuters.com; +41 41 528 3630; Reuters
Messaging: michael.shields.thomsonreuters.com@reuters.net))